Use of Data Monitoring Committees in Clinical Trials, Guidance for Industry （draft guidance）——interpret the development and practice of Data Monitoring Committee from the updated FDA guidelines

ZHENG Yu, DANG Hai-xia, LIU Jun, WANG Zhong, YU Ya-nan

PDF(860 KB)
PDF(860 KB)
Chinese Journal of New Drugs ›› 2026, Vol. 35 ›› Issue (5) : 470-475. DOI: 10.20251/j.cnki.1003-3734.2026.05.005

Use of Data Monitoring Committees in Clinical Trials, Guidance for Industry （draft guidance）——interpret the development and practice of Data Monitoring Committee from the updated FDA guidelines

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2026, 35(5): 470-475 https://doi.org/10.20251/j.cnki.1003-3734.2026.05.005

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(860 KB)

Accesses

Citation

Detail
Sections
Recommended
Total:
Copyright © Chinese Journal of New Drugs, All Rights Reserved.
Tel: 010-52722697 | 010-52723707
　 Powered by Beijing Magtech Co., Ltd.

/

〈 〉